Table 4. Association of Statin Therapy at Discharge Stratified by eGFR with Mortality and Unfavorable Outcome at 3 Months After Ischemic Stroke.

	Mortality		Unfavorable outcome
	Crude HR	Adjusted HR	Crude HR	Adjusted HR
eGFR (mL/min/1.73 m2)	(95% CI)	(95% CI)	(95% CI)	(95% CI)
≥ 90	0.21 (0.12, 0.39)	0.46 (0.24, 0.89)	0.88 (0.79, 0.97)	0.91 (0.81, 1.02)
60–89	0.27 (0.20, 0.37)	0.45 (0.32, 0.64)	0.85 (0.80, 0.91)	0.92 (0.86, 0.99)
30–59	0.29 (0.22, 0.39)	0.49 (0.36, 0.68)	0.89 (0.83, 0.95)	0.98 (0.91, 1.06)
15–29	0.34 (0.21, 0.57)	0.53 (0.31, 0.91)	0.94 (0.81, 1.10)	0.97 (0.82, 1.15)
< 15 non-dialysis	0.40 (0.17, 0.94)	0.74 (0.29, 1.89)	0.78 (0.57, 1.06)	0.77 (0.54, 1.08)
Dialysis	0.39 (0.20, 0.79)	0.67 (0.32, 1.39)	0.97 (0.76, 1.24)	1.05 (0.80, 1.37)

HR, hazard ratio; CI, confidence intervals; eGFR, estimated glomerular filtration rate.

The adjusted variables included age, gender, admission NIHSS, hypertension, diabetes, hypercholesterolemia, hypertriglyceridemia, previous cerebral infarction, previous cerebral hemorrhage, ischemic heart disease, ischemic stroke subtype, atrial fibrillation, peripheral arterial disease, alcohol consumption, cancer, antiplatelet/anticoagulant use after admission, and intravenous thrombolysis.